> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/pentose-phosphate-pathway.md).

# pentose phosphate pathway

{% hint style="info" %}
**Section:** Complete Biochemistry → Coenzyme Pathways\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Well established (biochemistry); preclinical or mixed (therapeutic applications, labelled below)
{% endhint %}

## Summary

The **pentose phosphate pathway (PPP)** is a branch of glucose metabolism that produces **NADPH** (for antioxidant defence and building fats) and **ribose-5-phosphate** (for DNA, RNA and nucleotide cofactors). Its second half, the non-oxidative branch, depends on **transketolase**, the only TPP-dependent enzyme in the pathway. Transketolase reshuffles sugar phosphates so that the cell can balance its needs for NADPH, ribose and energy.

Transketolase is also the enzyme measured in the **erythrocyte transketolase test** for thiamine status. It has been studied as a target for preventing diabetic complications, and it is implicated in a rare inherited syndrome.

## Key facts

| Property               | Detail                                                                                   |
| ---------------------- | ---------------------------------------------------------------------------------------- |
| **Enzyme**             | Transketolase (TKT), EC 2.2.1.1                                                          |
| **Location**           | Cytosol                                                                                  |
| **Structure**          | Homodimer; two active sites at the subunit interface                                     |
| **Cofactors**          | TPP and a divalent cation (Mg²⁺ or Ca²⁺)                                                 |
| **Reaction type**      | Transfer of a two-carbon (glycolaldehyde) unit from a ketose donor to an aldose acceptor |
| **Partner enzyme**     | Transaldolase (not TPP-dependent)                                                        |
| **Clinical test**      | Erythrocyte transketolase activity and TPP effect                                        |
| **Inherited disorder** | Transketolase deficiency (*TKT*)                                                         |

## The pathway

### Oxidative branch (irreversible, NADPH-producing)

| Step                                            | Enzyme                                   | Product   |
| ----------------------------------------------- | ---------------------------------------- | --------- |
| Glucose-6-phosphate → 6-phosphogluconolactone   | Glucose-6-phosphate dehydrogenase (G6PD) | **NADPH** |
| 6-Phosphogluconolactone → 6-phosphogluconate    | 6-Phosphogluconolactonase                | —         |
| 6-Phosphogluconate → ribulose-5-phosphate + CO₂ | 6-Phosphogluconate dehydrogenase         | **NADPH** |

### Non-oxidative branch (reversible, sugar interconversion)

| Reaction                                                              | Enzyme                         | TPP-dependent? |
| --------------------------------------------------------------------- | ------------------------------ | -------------- |
| Ribulose-5-P ⇌ ribose-5-P                                             | Ribose-5-phosphate isomerase   | No             |
| Ribulose-5-P ⇌ xylulose-5-P                                           | Ribulose-5-phosphate epimerase | No             |
| Xylulose-5-P + ribose-5-P ⇌ glyceraldehyde-3-P + sedoheptulose-7-P    | **Transketolase**              | **Yes**        |
| Sedoheptulose-7-P + glyceraldehyde-3-P ⇌ erythrose-4-P + fructose-6-P | Transaldolase                  | No             |
| Xylulose-5-P + erythrose-4-P ⇌ glyceraldehyde-3-P + fructose-6-P      | **Transketolase**              | **Yes**        |

**Net non-oxidative result:** 3 pentose phosphates ⇌ 2 fructose-6-phosphate + 1 glyceraldehyde-3-phosphate. These products can enter glycolysis, or the reactions can run in reverse to make ribose from glycolytic intermediates.

## Transketolase mechanism

{% stepper %}
{% step %}

### The TPP ylide attacks the ketose donor

The TPP ylide attacks C2 of the **ketose donor** (for example, xylulose-5-phosphate).
{% endstep %}

{% step %}

### The donor bond breaks

The C2–C3 bond breaks, releasing an aldose product (glyceraldehyde-3-phosphate) and leaving a two-carbon **α,β-dihydroxyethyl-TPP** carbanion on the enzyme.
{% endstep %}

{% step %}

### The carbanion attacks the aldose acceptor

This carbanion attacks the carbonyl carbon of the **aldose acceptor** (ribose-5-phosphate or erythrose-4-phosphate).
{% endstep %}

{% step %}

### The ketose is released

The new, two-carbon-longer ketose is released and the ylide regenerated.
{% endstep %}
{% endstepper %}

Transaldolase, by contrast, transfers a three-carbon unit using a lysine Schiff-base mechanism and needs no cofactor.

## Flexible modes of operation

Because the non-oxidative branch is reversible, the pathway adapts to cellular needs:

| Cellular need                                                     | Pathway operation                                                             | Role of transketolase   |
| ----------------------------------------------------------------- | ----------------------------------------------------------------------------- | ----------------------- |
| **More ribose than NADPH** (e.g. rapidly dividing cells)          | Glycolytic intermediates converted to ribose-5-P without the oxidative branch | Runs "in reverse"       |
| **Balanced ribose and NADPH**                                     | Oxidative branch only                                                         | Minimal                 |
| **More NADPH than ribose** (e.g. fat synthesis, oxidative stress) | Pentoses recycled to glucose-6-P for repeated oxidative passes                | Essential for recycling |
| **NADPH and ATP**                                                 | Pentoses converted to glycolytic intermediates and oxidized                   | Feeds glycolysis        |

Transketolase does not produce NADPH directly. By recycling pentoses, however, it allows the oxidative branch to keep generating NADPH when demand is high.

## Physiological importance

* **Nucleotide synthesis:** ribose-5-phosphate for DNA, RNA, ATP, NAD⁺, FAD and coenzyme A.
* **Antioxidant defence:** NADPH regenerates reduced glutathione via glutathione reductase.
* **Biosynthesis:** NADPH drives fatty acid, cholesterol and steroid synthesis. The PPP is especially active in liver, adipose tissue, adrenal glands and lactating mammary gland.
* **Immune function:** NADPH oxidase in phagocytes uses NADPH to produce microbicidal oxidants.
* **Red blood cells:** depend on the PPP for NADPH to protect against oxidative damage.
* **Nervous system:** NADPH supports antioxidant defence and lipid (including myelin) synthesis. Reduced transketolase activity has been proposed to contribute to oxidative stress in thiamine deficiency. This is supported by animal studies but not established in humans.

## Transketolase as a thiamine biomarker

Red blood cells contain transketolase. Its activity, measured with and without added TPP, indicates whether the enzyme is saturated with coenzyme. This is the basis of the erythrocyte transketolase activity (ETKA) test and its activation coefficient. The test has important limitations, including falsely normal results when prolonged deficiency reduces the amount of enzyme protein (see [Testing Limitations](broken://pages/1413ea1d53e19f9a39d0758ef8331327b1cf2bc4)).

## Transketolase variants and Wernicke-Korsakoff syndrome

In 1977, Blass and Gibson reported that transketolase from cultured cells of some people with Wernicke-Korsakoff syndrome had **reduced affinity for TPP**. This suggested a genetic vulnerability. However:

* Later sequencing of the transketolase coding region found **no consistent differences** between people with and without the syndrome.
* Association studies of *TKT* variants have been inconsistent.

The idea that inherited differences contribute to vulnerability remains plausible, but a specific transketolase variant has not been established.

## Transketolase in diabetes research

High blood glucose increases levels of glycolytic intermediates (fructose-6-phosphate and glyceraldehyde-3-phosphate). These feed pathways linked to diabetic complications, including advanced glycation end-product formation, protein kinase C activation and the hexosamine pathway.

| Finding                                                                                                                                                        | Study type                     | Strength                    |
| -------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------ | --------------------------- |
| Benfotiamine activated transketolase, diverted these intermediates into the PPP, blocked three damage pathways and prevented experimental diabetic retinopathy | Animal and cell studies (2003) | **Preclinical**             |
| High-dose thiamine and benfotiamine prevented early diabetic nephropathy in rats                                                                               | Animal study (2003)            | **Preclinical**             |
| Benfotiamine for 12 weeks did not reduce urinary albumin excretion in type 2 diabetic nephropathy                                                              | Randomized controlled trial    | **No effect** in this trial |
| Benfotiamine for 24 months did not improve nerve function or inflammatory markers in type 1 diabetes                                                           | Randomized controlled trial    | **No effect** in this trial |

The transketolase-activation hypothesis is mechanistically compelling and well supported in animals. It has **not been confirmed by clinical outcome trials in humans** to date. See [Benfotiamine](broken://pages/75effe2f75d8702a4645b72eb76b7a3b69392e6d).

## Transketolase deficiency

Inherited transketolase deficiency, described in 2016, causes a syndrome of short stature, developmental delay and congenital heart defects. Affected individuals have elevated **polyols** (such as erythritol and arabitol) and sugar phosphates in body fluids. It is not known to be thiamine-responsive.

## Transketolase-like protein 1 (TKTL1)

*TKTL1* encodes a protein related to transketolase. It has been proposed to drive a glucose-fermenting metabolism in some cancers. However, TKTL1 lacks some sequence features thought necessary for transketolase activity, and **whether it has catalytic activity in vivo is disputed**. Claims about TKTL1 as a cancer biomarker or treatment target should be read with this uncertainty in mind.

## Thiamine, transketolase and cancer metabolism

Rapidly dividing cells use the non-oxidative PPP to make ribose. This has prompted research into thiamine and cancer, with findings pointing in different directions.

| Finding                                                                                                | Study type              | Interpretation                                        |
| ------------------------------------------------------------------------------------------------------ | ----------------------- | ----------------------------------------------------- |
| Oxythiamine (a transketolase and PDH inhibitor) reduced ribose synthesis and tumour cell proliferation | Cell and animal studies | Supports transketolase as a research target           |
| Moderate thiamine supplementation increased tumour growth, while very high doses reduced it            | Mouse tumour model      | Dose-dependent and non-linear                         |
| High-dose thiamine reduced proliferation of some cancer cell lines, possibly by reactivating PDH       | Cell studies            | Mechanism resembles the PDK inhibitor dichloroacetate |

{% hint style="warning" %}
**Evidence note:** these findings come from cell and animal models with very different doses from those used in humans. Whether thiamine intake meaningfully affects cancer growth in people is **unknown**. People with cancer should discuss supplements with their oncology team.
{% endhint %}

## Evidence quality

| Claim type                                                 | Strength                                                                     |
| ---------------------------------------------------------- | ---------------------------------------------------------------------------- |
| PPP reactions and transketolase mechanism                  | **Strong**                                                                   |
| Transketolase as a thiamine status marker                  | **Strong** for concept; **moderate** for clinical utility (see testing page) |
| Transketolase activation preventing diabetic complications | **Strong** preclinical; **not supported** by human outcome trials so far     |
| Transketolase variants in Wernicke-Korsakoff vulnerability | **Uncertain**                                                                |
| TKTL1 catalytic role in cancer                             | **Disputed**                                                                 |
| Thiamine effects on cancer growth                          | **Preclinical and conflicting**                                              |

## Open questions

* Whether impaired transketolase-dependent NADPH regeneration contributes to tissue damage in human thiamine deficiency.
* Whether specific patient groups, such as people with diabetes and low thiamine status, benefit from transketolase-targeted strategies.
* How thiamine supply affects PPP flux in tumours in people, if at all.

## Related pages

* [TPP-Dependent Enzymes](broken://pages/48b61d9218e12eeb5f0e1876c67ae5de17b143ff)
* [Oxidative Decarboxylation](broken://pages/aff327c1d64ad1abd2c61500f4b7cb2993cb7830)
* [Benfotiamine](broken://pages/75effe2f75d8702a4645b72eb76b7a3b69392e6d)
* [Testing Limitations](broken://pages/1413ea1d53e19f9a39d0758ef8331327b1cf2bc4)

## References

1. Schenk G, Duggleby RG, Nixon PF. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. *International Journal of Biochemistry & Cell Biology*. 1998;30(12):1297–1318.
2. Stincone A, et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. *Biological Reviews*. 2015;90(3):927–963.
3. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff syndrome. *New England Journal of Medicine*. 1977;297(25):1367–1370.
4. McCool BA, et al. Cloning of human transketolase cDNAs and comparison of the nucleotide sequence of the coding region in Wernicke-Korsakoff and non-Wernicke-Korsakoff individuals. *Journal of Biological Chemistry*. 1993;268(2):1397–1404.
5. Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. *Nature Medicine*. 2003;9(3):294–299.
6. Babaei-Jadidi R, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes*. 2003;52(8):2110–2120.
7. Alkhalaf A, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. *Diabetes Care*. 2010;33(7):1598–1601.
8. Fraser DA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. *Diabetes Care*. 2012;35(5):1095–1097.
9. Boyle L, et al. Mutations in *TKT* are the cause of a syndrome including short stature, developmental delay, and congenital heart defects. *American Journal of Human Genetics*. 2016;98(6):1235–1242.
10. Coy JF, Dressler D, Wilde J, Schubert P. Mutations in the transketolase-like gene *TKTL1*: clinical implications for neurodegenerative diseases, diabetes and cancer. *Clinical Laboratory*. 2005;51(5–6):257–273.
11. Boros LG, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. *Cancer Research*. 1997;57(19):4242–4248.
12. Comín-Anduix B, et al. The effect of thiamine supplementation on tumour proliferation: a metabolic control analysis study. *European Journal of Biochemistry*. 2001;268(15):4177–4182.
13. Hanberry BS, Berger R, Zastre JA. High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate. *Cancer Chemotherapy and Pharmacology*. 2014;73(3):585–594.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
